![Henrik Olsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Henrik Olsen
Corporate Officer/Principal at Gliknik, Inc.
Henrik Olsen active positions
Companies | Position | Start | End |
---|---|---|---|
Gliknik, Inc.
![]() Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Corporate Officer/Principal | - | - |
Career history of Henrik Olsen
Former positions of Henrik Olsen
Companies | Position | Start | End |
---|---|---|---|
Human Genome Sciences, Inc.
![]() Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Chief Tech/Sci/R&D Officer | - | - |
Training of Henrik Olsen
University of Aarhus | Undergraduate Degree |
Statistics
International
United States | 3 |
Denmark | 2 |
Operational
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Gliknik, Inc.
![]() Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Health Technology |
Human Genome Sciences, Inc.
![]() Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
- Stock Market
- Insiders
- Henrik Olsen
- Experience